NCT00079144View on ClinicalTrials.gov

Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL

Timeline

Start Date

January 31, 2004

Study Completion Date

August 31, 2005

Conditions

Melanoma (Skin)

Interventions

BIOLOGICAL

NY-ESO-1 peptide vaccine

BIOLOGICAL

aldesleukin

BIOLOGICAL

filgrastim

BIOLOGICAL

incomplete Freund's adjuvant

BIOLOGICAL

therapeutic autologous lymphocytes

DRUG

cyclophosphamide

DRUG

fludarabine phosphate

Trial Locations (2)

20892

NCI - Center for Cancer Research, Bethesda

20892-1182

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00079144 - Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma | Biotech Hunter | Biotech Hunter